Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 15/20 | 0.47 |
| ▸ | CCR3 | P51677 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | HTR1D | P28221 | 1/20 | 0.42 |
| ▸ | HTR1B | P28222 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3204594 | 1.00 | ACKR3 (0.47) | ACKR3CCR3HTR1AHTR1DHTR1B | |
| SCHEMBL402086 | 0.81 | ACKR3 (0.51) | ACKR3CCR3HTR1AHTR1DHTR1B | |
| SCHEMBL10315552 | 0.80 | ACKR3 (0.57) | ACKR3HTR1AHTR1DHTR1BNPSR1 | |
| SCHEMBL3198046 | 0.79 | ACKR3 (0.52) | ACKR3CCR3HTR1AHTR1DHTR1B | |
| SCHEMBL401714 | 0.79 | ACKR3 (0.49) | ACKR3CCR3HTR1AHTR1DHTR1B | |
| SCHEMBL398679 | 0.78 | ACKR3 (0.51) | ACKR3CCR3HTR1AHTR1DHTR1B | |
| SCHEMBL8242499 | 0.77 | ACKR3 (0.51) | ACKR3CCR3HTR1AHTR1DHTR1B | |
| SCHEMBL3189536 | 0.75 | RORC (0.42) | CCR3NPSR1 | |
| SCHEMBL3206229 | 0.75 | RORC (0.42) | CCR3NPSR1 | |
| SCHEMBL3205533 | 0.75 | RORC (0.42) | CCR3NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161617-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | claimed |
| US-8871768-B2 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130324549-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| US-8445495-B2 | Certain Chemical entities, compositions and methods | CYTOKINETICS, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20100029680-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2010-02-04 | — | — | US | disclosed |
| EP-1959960-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20070161617-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
| WO-2007070683-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161617-A1 | Certain chemical entities, compositions and methods | TNNI3, TNNT2, MYLK2 | ACKR3 4779/4885CCR3 4640/4885HTR1A 4023/4885 |
| US-20130324549-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | TNNI3, TNNT2, MYLK2 | ACKR3 4779/4885CCR3 4640/4885HTR1A 4023/4885 |
| US-20100029680-A1 | Certain Chemical Entities, Compositions and Methods | TNNI3, TNNT2, MYLK2 | ACKR3 4779/4885CCR3 4640/4885HTR1A 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.